Loading
A phase 2 trial of Toripalimab, Paclitaxel / nab-paclitaxel in head and neck squamous cell carcinoma, run by Lyvgen Biopharma Holdings Limited, active and no longer recruiting.
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) is a phase 2 interventional study registered as NCT06378177 by Lyvgen Biopharma Holdings Limited, with 64 participants planned, started 2024-06-21 and due to reach its primary completion in 2027-10-31. Interventions recorded: LVGN6051 Monoclonal Antibody Injection, toripalimab Injection, Paclitaxel injection. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Immune checkpoint inhibitors.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Immune checkpoint inhibitors.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Immune checkpoint inhibitors.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Immune checkpoint inhibitors.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma, Immune checkpoint inhibitors.